论文部分内容阅读
目的评价中药益髓生血颗粒联合西药羟基脲治疗中间型β地中海贫血(thalassemia intermedia,TI)的临床疗效。方法 60例TI患者随机分成3组,分别口服益髓生血颗粒、口服羟基脲以及同时口服益髓生血颗粒和羟基脲3个月。治疗前后分别检测3组患者血红蛋白(hemoglobin,Hb)、胎儿血红蛋白(fetal hemoglobin,Hb F)、白细胞(white blood cell,WBC),并记录不良反应。结果 57例按试验方案完成治疗和检查,联合用药组Hb和Hb F升高程度优于益髓生血颗粒组和羟基脲组(P<0.05),3组WBC改变无明显差异。结论益髓生血颗粒联合羟基脲进一步提升Hb和Hb F,使TI患者贫血症状减轻。
Objective To evaluate the clinical efficacy of Yisui Shengxue granule combined with hydroxyurea in the treatment of middle-class β thalassemia intermedia (TI). Methods Sixty patients with TI were randomly divided into three groups: oral administration of Yisan Shengxue Granule, oral administration of hydroxyurea and simultaneous administration of Yisa Shengxue granule and hydroxyurea for 3 months. Before and after treatment, hemoglobin (Hb), fetal hemoglobin (Hb F) and white blood cell (WBC) were measured in 3 groups, and the adverse reactions were recorded. Results 57 cases were treated and tested according to the experimental protocol. The levels of Hb and Hb F in the combination group were better than those in the Yisui Shengxue granule group and the hydroxyurea group (P <0.05). There was no significant difference in WBC in the 3 groups. Conclusion Yisheng Shengxue granule combined with hydroxyurea to further enhance Hb and Hb F, so that patients with TI reduce the symptoms of anemia.